Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Nashville, Tennessee 37232


Purpose:

This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths. This study will also investigate the levels of CTAP201 in the body over time and determine the safety of CTAP201.


Criteria:

Inclusion Criteria: - Body mass index between 18 and 40 - On maintenance hemodialysis three times per week - Visit 1: Serum iPTH value greater than or equal to 200 pg/mL and lower than or equal to 1000 pg/mL - Visit 1: Serum total calcium value greater than 8.4 mg/dL and lower than 10.0 mg/dL - Visit 1: Serum phosphorus value greater than or equal to 2.5 mg/dL and lower than or equal to 5.5 mg/dL - Serum 25-hydroxyvitamin D level greater than or equal to 15 ng/mL - Visit 2: Serum iPTH value greater than 300 pg/mL - Visit 2: Serum Ca x P product less than 56 [mg/dl]2 - Willing and able to discontinue vitamin D and/or bone metabolism therapy for at least 2 weeks prior to administration of Study Drug, and length of study Exclusion Criteria: - Taking cytochrome P450 3A inhibitors and/or inducers - Abnormal liver functions


NCT ID:

NCT00792857


Primary Contact:

Study Director
Joel Melnick, MD
OPKO Renal


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.